Last reviewed · How we verify
NCT06940895
Evaluating the Safety and Efficacy of Topical Sirolimus 0.2% to Treat Acanthosis Nigricans
Phase 2 trial testing Sirolimus 0.2% in Acanthosis Nigricans in 5 participants. Completed in 18 July 2025.
8 July 2025
Quick facts
| Lead sponsor | Narrows Institute for Biomedical Research |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 5 |
| Start date | 1 March 2025 |
| Primary completion | 8 July 2025 |
| Estimated completion | 18 July 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Sirolimus 0.2% — full drug profile →
Conditions studied
- Acanthosis Nigricans — all drugs for Acanthosis Nigricans →
Sponsor
Narrows Institute for Biomedical Research
Who can join
18 and older, any sex, with Acanthosis Nigricans. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to demonstrate the safety and efficacy of Sirolimus 0.2% topical gel for patients with Acanthosis Nigricans
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06940895
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sirolimus 0.2%
Trials testing the same drug.
- NCT03363763 — Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex · Phase 2 · terminated
Other recruiting trials for Acanthosis Nigricans
Currently open trials in the same condition.
- NCT06331819 — Clinical Association Between Obstructive Sleep Apnea, Facial Pigmentation, and Vasovagal Symptoms. · recruiting
Other Narrows Institute for Biomedical Research trials
Trials by the same sponsor.
- NCT06952517 — Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea · Phase 2 · recruiting
- NCT06938815 — A Novel Regimen for Treatment and Prevention of Post-Inflammatory Hyperpigmentation in Skin of Color · NA · completed
- NCT04169100 — Novel Form of Acquired Long QT Syndrome · Phase 4 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06940895 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Narrows Institute for Biomedical Research
- Last refreshed: 28 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06940895.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing